Tempest Therapeutics, Inc. ( (TPST) ) has released its Q3 earnings. Here is a breakdown of the information Tempest Therapeutics, Inc. presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapies for cancer treatment, featuring a diverse product portfolio and a lead program, amezalpat, targeting liver cancer. The company’s recent earnings report highlights an increase in operating expenses and a net loss, reflecting ongoing investments in research and development as it progresses toward pivotal clinical trials. Tempest reported a cash position of $22.1 million as of September 30, 2024, down from $39.2 million at the end of 2023, indicating a significant cash outflow due to increased operational activities. The company has successfully raised additional funds through an at-the-market offering to support its clinical programs. Looking ahead, Tempest’s management remains focused on advancing its pipeline, particularly the amezalpat program, while actively seeking additional financing to sustain its operations and bring its promising candidates to market.
